PRFX Projected Dividend Yield

PainReform Ltd ( NASDAQ : PRFX )

PainReform is a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics. Co.'s extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates. PRF-110, Co.'s first product candidate, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia.

20 YEAR PERFORMANCE RESULTS